Andrew Levitch

Andrew Levitch

Andrew Levitch joined FLG in 2021. Andrew is an innovative, results-driven executive with significant experience leading strategic, financial and operations teams in life sciences and technology companies in the biotech, medical device, diagnostic, digital health, and manufacturing sectors, ranging from Fortune 50 to venture-backed startups.

Prior to joining FLG, Andrew founded Finategy, a strategic advisory firm that provided C-suite and strategic advisory services to Private Equity & Venture backed companies and Merck’s Global Health Innovation fund.  While running Finategy, Andrew held CEO, CFO and COO roles as well as Board member/observer positions. Andrew has implemented operational efficiencies that have led to millions in annual savings and has been involved in raising over $200 million in equity and debt financing, as well as exit strategy development and execution.  As an advisor to Merck’s Global Health Innovation fund Andrew performed diligence and valuations on initial and follow-on investments resulting in $150M+ in equity and debt financing, delivered operational assessments on portfolio companies in order to successfully address issues, participated in Ecosystem strategy development and was a member of an integration team that was responsible for integrating a fund acquisition.  The following is a representative list of Andrew’s consulting clients: Eliaz Therapeutics, Cancer Prevention Pharmaceuticals, Cancer Expert Now, Geritrex, C3i Solutions, medCPU, Preventice Solutions (acquired by Boston Scientific (NYSE: BSX)), AdvanDx, Locemia Solutions, Avir, Unitaid, Top 10 Pharma Co, Daktari Diagnostics, and Merck. Andrew served on Decipher Biosciences (acquired by Veracyte (NASDAQ: VCYT) and VirtualScopics’ (NASDAQ: VSCP now part of Philips (NYSE: PHG)) Board of Directors and was a member of VirtualScopics Audit committee.

Previously, Andrew spent 16 years at Merck in strategic, operational, finance, and marketing roles of increasing responsibility. Andrew’s final role at Merck was Senior Director, Global Scientific Strategy – Portfolio Management, and chair of the Research divisions capital committee. Earlier at Merck, Andrew was on diligence teams for M&A and licensing deals, led the integration and was the CFO / COO of Sirna Therapeutics (post the $1B acquisition), was the business partner to the leader of the Oncology and advanced technologies area, held a business analysis and planning role within the R&D division, served as the CFO for the Hypertension / Heart failure franchise when US sales were in excess of $2B, and held roles within the Merial animal health joint venture and manufacturing finance.

Andrew started his career working for regional accounting firms and served in the U.S. Navy. He received his B.S. in Accounting from Rutgers College of Business and his M.B.A. from Lehigh University. He is a CPA (inactive) in PA and NJ. Andrew resides in the New York Metro Area.